Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Clostridium Difficile Infection (CDI)
Interventions: Fidaxomicin, Vancomycin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Ypsilanti, Michigan

Conditions: Arthropathy of Knee Joint
Interventions: Vancomycin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions: vancomycin or gentamicin, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Infection Due to Resistant Organism
Interventions: Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling, Fasting; Biological · Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Skin Structures and Soft Tissue Infections
Interventions: Iclaprim, Vancomycin; Drug
Lead sponsor: Motif Bio; Industry
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 12 more

Conditions: Influenza
Interventions: Synbiotic AKSB; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Open Fracture
Interventions: Vancomycin (VAN) treatment, Standard Open Fracture Care; Drug · Other
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions: Single-Dose IV Oritavancin Diphosphate, IV Vancomycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions: Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more

Conditions: Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions: Vancomycin, Daptomycin, Semi-Synthetic Penicillin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Azusa, California • Los Angeles, California • Torrance, California + 7 more

Conditions: Surgical Wound Infections
Interventions: Vancomycin, Placebo (Saline Solution); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Bacterial Infections, Infection
Interventions: BC-3781, Vancomycin; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 6 more

Conditions: Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Metronidazole, Neomycin, Nivolumab, Pembrolizumab, Questionnaire Administration, Vancomycin; Procedure · Drug · Biological + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Necrotizing Soft Tissue Infection
Interventions: Antibiotic duration (short course), Antibiotic duration (extended course); Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Hematopoietic Stem Cell Transplantation, Vancomycin-Resistant Enterococci
Interventions: Theraworx™ bath wipes, Standard bath wipes; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,096 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
Interventions: doxycycline, vancomycin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions: vancomycin, Miralax, intestinal microbiota, placebo vancomycin, Miralax, placebo intestinal microbiota; Combination Product
Lead sponsor: Arizona State University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Osteomyelitis
Interventions: daptomycin, vancomycin, teicoplanin, nafcillin, oxacillin, flucloxacillin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 17
States / cities: Little Rock, Arkansas • Englewood, Colorado • Washington D.C., District of Columbia + 14 more

Conditions: Healthy Volunteer, Hypersensitivity Reactions, Vancomycin
Interventions: Vancomycin (IV); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Interventions: MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole; Drug
Lead sponsor: Metagen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Naples, Florida • Boston, Massachusetts • New York, New York

Conditions: Crohn Disease
Interventions: Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Fluconazole; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rabies Human
Interventions: Rabies Vaccine, Metronidazole, Vancomycin, Neomycin Sulfate; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Decatur, Georgia

Search by objective public record fields.

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

FMT for MDRO Colonization After Infection in Renal Transplant Recipients

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2

Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly

Implementation of Vancomycin Powder Application in the Emergency Department for Open Fractures

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

Prevention of Neurosurgical Wound Infections

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

MTT for Children With ASD Who Have Gastrointestinal Disorders

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions

Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Responses to Rabies Vaccine in Adults With or Without Antibiotics